Cardiovascular collaboration
Cryptome Pharmaceuticals has signed a memorandum of understanding with the University of Queensland's Institute for Molecular Biosciences (IMB) to collaborate on the identification of potential therapeutics for cardiovascular disease.
The IMB will provide Cryptome with high value compound libraries, which Cryptome will screen for potential activity using its proprietary Cryptomics platform technology. The Cryptomics drug discovery platform is based on finding small protein fragments with previously undiscovered therapeutic activities. These fragments are generated, screened and identified using the Cryptomics systematic high-throughput approach.
NSW Health and Cicada partner on medtech training program
The NSW Health Commercialisation Training Program is a free training program for NSW-based...
Sinocompound Catalysts launches educational video series
The first episode of the video series is now live and focuses on palladium catalysed...
AACB conference coming to Brisbane
The 58th AACB Annual Scientific Conference will be held at Brisbane's Royal International...
